share_log

基石药业-B(02616.HK)与Pharmalink就舒格利单抗在中东和非洲地区达成战略合作

Cornerstone Pharmaceuticals-B (02616.HK) has reached a global strategy cooperation with Pharmalink regarding Sugrilimab in the Middle East and Africa.

Gelonghui Finance ·  Nov 21, 2024 08:02

Gelonghui November 21丨Cornerstone Pharmaceutical-B (02616.HK) announced that the company reached a commercial strategic cooperation with Pharmalink Store-L.L.C - O.P.C (“Pharmalink”). Pharmalink is a well-known pharmaceutical company headquartered in the United Arab Emirates. Under the licensing and commercialization agreement, Pharmalink will obtain commercialization rights for sugarimab in the Middle East and North Africa, including Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, Algeria, Tunisia, Egypt, Morocco, Libya, and South Africa.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment